Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma
Metrics: PDF 952 views | HTML 1622 views | ?
Lin Yurong1, Rong Biaoxue1, Li Wei1, Ming Zongjuan1, Shi Hongyang1, Fang Ping1, Gao Wenlong2, Yang Shuanying1, Li Zongfang3
1Department of Respiratory Medicine, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China
2Department of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China
3Department of Elderly Surgery, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China
Keywords: stathmin, lung adenocarcinoma, shRNA, tumor growth, proliferation
Received: February 21, 2016 Accepted: July 09, 2016 Published: August 02, 2016
Stathmin has been investigated as a tumor biomarker because it appear to be associated with tumorigenesis; however, the effect of stathmin in lung adenocarcinoma (LAC) remains poorly understood. The purpose of this study was to examine the expression of stathmin in lung adenocarcinoma, and to disclose the relationship between them. The expression of stathmin was examined by RT-PCR, IHC and Western blot. Furthermore, small interfering RNA (shRNA)-mediated silencing of stathmin was employed in LAC cells to investigate cell proliferation, invasion and apoptosis. In this study, we showed that overexpression of stathmin was significantly associated with poorly differentiated, lymph node metastasis and advance TNM stages of lung adenocarcinoma. And silencing of stathmin expression inhibited the proliferation, migration and invasion of lung adenocarcinoma PC-9 cells, and retarded the growth of PC-9 cells xenografts in nude mice. Additionally, the anticarcinogenic efficacy of stathmin silencing might be involved in P38 and MMP2 signaling pathways. In conclusion, these results showed that stathmin expression was significantly up-regulated in LAC, which may act as a biomarker for LAC. Furthermore, silence of stathmin inhibiting LAC cell growth indicated that stathmin may be a promising molecular target for LAC therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.